Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S
Supreme Court of the United States
Decided April 17, 2012
Full case name	Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S
Citations	566 U.S. 399 ( more )
Holding
A generic manufacturer may employ the counterclaim provision of the Hatch-Waxman Act to force correction of a use code that inaccurately describes the brand's patent as covering a particular method of using a drug.
Court membership
Chief Justice John Roberts Associate Justices Antonin Scalia  · Anthony Kennedy Clarence Thomas  · Ruth Bader Ginsburg Stephen Breyer  · Samuel Alito Sonia Sotomayor  · Elena Kagan
Case opinions
Majority	Kagan, joined by unanimous
Concurrence	Sotomayor
Laws applied
Drug Price Competition and Patent Term Restoration Act of 1984

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 566 U.S. 399(2012), was a United States Supreme Court case in which the court held that a generic manufacturer may employ the counterclaim provision of the Drug Price Competition and Patent Term Restoration Act of 1984 to force correction of a use code that inaccurately describes the brand's patent as covering a particular method of using a drug. ^{[1] [2]}

References

1. Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 566 U.S. 399 (2012).
2. Mann, Ronald (April 18, 2012). "Opinion analysis: Courts purposive reading hands Federal Circuit second patent reversal of the Term". SCOTUSblog. Retrieved October 12, 2025.

External links

• Text of Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 566 U.S. 399(2012) is available from: Justia

This article incorporates written opinion of a United States federal court. As a work of the U.S. federal government, the text is in the public domain .